Literature DB >> 18797405

Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.

Romualdo Belardinelli1, Francesca Lacalaprice, Ernesto Faccenda, Loretta Volpe.   

Abstract

BACKGROUND: Patients referred for cardiac rehabilitation may take advantage from combining trimetazidine (TMZ) with exercise training (ET), as both treatments produce similar effects in the cardiovascular system. It is, however, unknown whether the combination of TMZ with ET may determine greater improvements in functional capacity and endothelial function than ET alone.
DESIGN: A randomized longitudinal controlled study.
METHODS: We studied 116 patients (97 men and 19 women, mean age 58+/-9 years) with ischemic heart disease and left ventricular dysfunction who were referred for cardiac rehabilitation. Coronary risk factors were present in 82 patients (diabetes in 28 patients). Patients were randomized into three matched groups. A group (TMZ+training, TT, n=30) received TMZ at doses of 20 mg three times daily orally for 8 weeks in addition to standard medications and underwent a supervised program of ET at 60% of oxygen uptake at peak, three times a week for 8 weeks. A group (exercise, E, n=30) completed the ET program without receiving TMZ. A control group (C, n=26) was neither exercised nor received TMZ. A fourth group (TMZ, n=30) receiving TMZ 20 mg three times daily for 8 weeks was also studied. On study entry and at 8 weeks all patients underwent echocardiography, cardiopulmonary exercise testing, and vasomotor reactivity of the brachial artery.
RESULTS: Oxygen uptake at peak was significantly increased in the TT (25%), TMZ (15.1%), and E group (15.3%) (P<0.001 TT vs. C; P<0.05 vs. TMZ and E). Left ventricular ejection fraction was also improved in TT (18.4%), TMZ (15.7%), and E (12.9%) (P<0.001 TT vs. C; P<0.05 vs. TMZ and E), as a result of reduction in end-systolic volume. The endothelium-dependent dilation was similarly improved (P<0.001 TMZ vs. C; P<0.05 vs. TMZ and E). The most significant improvements were observed in the subgroup TT with multiple risk factors.
CONCLUSION: The addition of TMZ to ET determined greater improvements in functional capacity, left ventricular ejection fraction, and endothelium-dependent dilation than TMZ or ET given alone. No differences between improvements after TMZ and E as compared with controls were observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18797405     DOI: 10.1097/HJR.0b013e328304feec

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  11 in total

1.  Metabolic Therapy in Heart Failure.

Authors:  Yury Lopatin
Journal:  Card Fail Rev       Date:  2015-10

Review 2.  Trimetazidine and Other Metabolic Modifiers.

Authors:  Giacinta Guarini; Alda Huqi; Doralisa Morrone; Paola Francesca Giuseppina Capozza; Mario Marzilli
Journal:  Eur Cardiol       Date:  2018-12

Review 3.  Trimetazidine improves exercise tolerance in patients with ischemic heart disease : A meta-analysis.

Authors:  Y Zhao; L Peng; Y Luo; S Li; Z Zheng; R Dong; J Zhu; J Liu
Journal:  Herz       Date:  2015-12-14       Impact factor: 1.443

Review 4.  Skeletal muscle autophagy: a new metabolic regulator.

Authors:  Brian A Neel; Yuxi Lin; Jeffrey E Pessin
Journal:  Trends Endocrinol Metab       Date:  2013-10-29       Impact factor: 12.015

Review 5.  Metabolic Modulation of Cardiac Metabolism in Heart Failure.

Authors:  Giuseppe Mc Rosano; Cristiana Vitale
Journal:  Card Fail Rev       Date:  2018-08

Review 6.  Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials.

Authors:  Ammar W Ashor; Jose Lara; Mario Siervo; Carlos Celis-Morales; Clio Oggioni; Djordje G Jakovljevic; John C Mathers
Journal:  Sports Med       Date:  2015-02       Impact factor: 11.136

7.  Effects of trimetazidine in patients with severe chronic heart failure with reduced left ventricular ejection fraction: A prospective, randomized, open-label, cross-over study.

Authors:  Michał Bohdan; Iwona Stopczyńska; Piotr Wiśniewski; Joanna Moryś; Piotr Niedoszytko; Marcin Gruchała
Journal:  Cardiol J       Date:  2020-11-17       Impact factor: 3.487

8.  Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy - Six months follow-up result.

Authors:  A Momen; M Ali; P K Karmakar; M Z Ali; A Haque; M R Khan; M I Khalil; M S Hossain; R M Huda; M N Goni
Journal:  Indian Heart J       Date:  2016-04-13

9.  Meta-analysis of trimetazidine treatment for cardiomyopathy.

Authors:  Qian Fan; Zhaozhuo Niu; Liqing Ma
Journal:  Biosci Rep       Date:  2018-06-12       Impact factor: 3.840

10.  Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury.

Authors:  Ming Song; Fang-Fang Chen; Yi-Hui Li; Lei Zhang; Feng Wang; Ran-Ran Qin; Zhi-Hao Wang; Ming Zhong; Meng-Xiong Tang; Wei Zhang; Lu Han
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-11-19       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.